Home > Insider Trading > Filing (0000921895-15-002369)

Filing Details

Accession Number:: 0000921895-15-002369
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2015-11-05 17:34:55
Reporting Period:: 2015-11-03

Filing Date:: 2015-11-05
Accepted Time:: 2015-11-05 17:34:55
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1340652	Chemocentryx Inc.	CCXI	Pharmaceutical Preparations (2834)	943254365

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
918923	P L Fund Value Biotechnology	One Sansome Street 30Th Floor San Francisco CA 94104	No	No	No	Yes
1055947	P/Il L Partners Bvf	One Sansome Street 30Th Floor San Francisco CA 94104	No	No	No	Yes
1056807	Bvf Inc/Il	One Sansome Street 30Th Floor San Francisco CA 94104	No	No	No	Yes
1102444	Biotechnology Value Fund Ii Lp	One Sansome Street 30Th Floor San Francisco CA 94104	No	No	No	Yes
1132245	Bvf Investments Llc	One Sansome St 30Th Floor San Francisco CA 94104	No	No	No	Yes
1233840	N Mark Lampert	One Sansome Street 30Th Floor San Francisco CA 94104	No	No	No	Yes

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2015-11-03	73,000	$6.98	2,671,577	No	4	S	Indirect	See Explanation of Reponses
Common Stock	Disposition	2015-11-04	287,000	$7.00	2,384,577	No	4	S	Indirect	See Explanation of Reponses
Common Stock	Disposition	2015-11-05	2,384,577	$0.00	0	No	4	J	Indirect	See Explanation of Reponses

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	See Explanation of Reponses
No	4	S	Indirect	See Explanation of Reponses
No	4	J	Indirect	See Explanation of Reponses

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	2,162,381	Indirect	See Explanation of Reponses
Common Stock	1,251,914	Indirect	See Explanation of Reponses

Footnotes

This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), BVF Investments, L.L.C. ("BVFLLC"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13G group that no longer owns more than 10% of the Issuer's outstanding shares of Common Stock pursuant to Rule 16a-1(a)(1). Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.
Represents shares of Common Stock owned directly by BVF. As the general partner of BVF, Partners may be deemed to beneficially own the shares of Common Stock owned directly by BVF. As the investment adviser and general partner of Partners, BVF Inc., may be deemed to beneficially own the shares of Common Stock owned directly by BVF. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the shares of Common Stock owned directly by BVF.
Represents shares of Common Stock owned directly by BVF2. As the general partner of BVF2, Partners may be deemed to beneficially own the shares of Common Stock owned directly by BVF2. As the investment adviser and general partner of Partners, BVF Inc., may be deemed to beneficially own the shares of Common Stock owned directly by BVF2. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the shares of Common Stock owned directly by BVF2.
Represents shares of Common Stock owned directly by BVFLLC. As the manager of BVFLLC, Partners may be deemed to beneficially own the shares of Common Stock owned directly by BVFLLC. As the investment adviser and general partner of Partners, BVF Inc., may be deemed to beneficially own the shares of Common Stock owned directly by BVFLLC. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the shares of Common Stock owned directly by BVFLLC.
The shares of Common Stock are directly beneficially owned by BVFLLC, a Delaware limited liability company. Pursuant to the operating agreement of BVFLLC, BVF Partners, L.P., a Delaware limited partnership is authorized, among other things, to invest the contributed capital of Samana Capital, L.P., the majority member of BVFLLC, in the shares of Common Stock and other securities and to vote, exercise or convert and dispose of such securities and is entitled to receive fees based on assets under management and, subject to certain exceptions, allocations based on realized and unrealized gains on such assets.
Units may represent aggregation of daily trade activity. Details regarding individual execution amounts and prices are available upon request.
BVFLLC made an in-kind distribution of the shares to an account over which none of the Reporting Persons has investment discretion.
Pursuant to the November 5, 2015 distribution described in Footnote 7, BVFLLC no longer directly owns shares of Common Stock. As the manager of BVFLLC, Partners may have been deemed to beneficially own the shares of Common Stock previously owned directly by BVFLLC. As the investment adviser and general partner of Partners, BVF Inc., may have been deemed to beneficially own the shares of Common Stock previously owned directly by BVFLLC. As a director and officer of BVF Inc., Mr. Lampert may have been deemed to beneficially own the shares of Common Stock previously owned directly by BVFLLC.